36 results about "Macroglobulins" patented technology

The present invention relates to complexes of alpha (2) macroglobulin associated with antigenic molecules for use in immunotherapy. The invention relates to methods for using such compositions in the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.

The present invention provides a method of diagnosing the presence or severity of liver fibrosis in an individual by detecting α2-macroglobulin (α2-MG) in sample from the individual; detecting hyaluronic acid (HA) in a sample from the individual; detecting tissue inhibitor of a metalloproteinases-1 (TIMP-1) in a sample from the individual; and diagnosing the presence or severity of liver fibrosis in the individual based on the presence or level of α-MG, HA and TIMP-1.

The present invention relates to methods for the diagnosis of subjects that have or are at risk of having Alzheimer's disease (AD). In particular the present invention identifies individuals who have or are at risk of having AD through measurement of the levels of Afamin in combination with at least one other biomarker such as Alpha-1-antichymotrypsin, Alpha-2- macroglobulin, ApoB 100, Complement C5, Serine threonine protein kinase TBK1 or Complement C3 in a fluid sample taken from a subject. Furthermore, genotype (ApoIipoprotein E or glutathione S-transferase Omega) may also be taken into consideration and used within classification algorithms to determine the probability of a subject having or being at risk of having AD.

The present invention relates to the use of alpha (2) macroglobulin complexes isolated from the serum of a mammal. The invention also relates to methods for making such complexes and compositions comprising alpha (2) macroglobulin complexes, isolated from the serum of a mammal, wherein such compositions are used in methods for the treatment and prevention of cancer and infectious disease. The invention also relates to methods for treating and preventing cancer and infectious disease using such complexes comprising, isolated from the serum of a mammal. The invention also encompasses methods for production of alpha (2) macroglobulin complexes.

The invention concerns a method for the detection of the presence and / or the severity of a liver disease in a patient comprising measuring in an isolated sample TIMP-1 (Tissue Inhibitor of Metalloproteinase I), A2M (a-2-macroglobulin), PLT (number of blood plateletes, PI (prothrombin index), optionally at least one additional parameter selected from the group consisting of urea and GGT (γ-glutamyltranspeptidase) and optionally measuring at least one additional biochemical or clinical parameter and diagnosing the presence and / or severity of a liver disease based on the presence or measured levels of these parameters. The method can be used for monitoring therapeutic treatment of liver fibrosis and staging of liver fibrosis.

A high-sensitivity human urine alpha2-macroglobulin detection kit belongs to the field of detection kits and comprises a reagent R1, a reagent R2, a calibration product and a quality control product,wherein the reagent R1 contains a buffer solution, salt, an accelerant, an anti-interference agent and a preservative; the reagent R2 contains a buffer solution, antiserum, a stabilizer and a preservative; the calibration product contains a buffer solution, serum, a stabilizer and a preservative; the quality control product contains a buffer solution, serum, a stabilizer and a preservative; wherein the antiserum is anti-human alpha2-MG antiserum. The serum is human serum or animal serum. According to the invention, the sensitivity of the kit is improved by using a buffer solution compounding method; the content of alpha 2-macroglobulin in human urine is detected through immunoturbidimetry, a urine sample is directly tested on a machine without manual treatment, an anti-interference agent is added into the reagent, the sensitivity of the reagent is effectively improved, so that the test accuracy of the urine sample is improved, and the kit is suitable for various full-automatic biochemical analyzers and has wider universality.

The present invention relates to the use of alpha (2) macroglobulin (“α2M”) receptor as a heat shock protein receptor, cells that express the α2M receptor bound to an HSP, and antibodies and other molecules that bind the α2M receptor-HSP complex. The invention also relates to screening assays to identify compounds that interact with the α2M receptor, and modulate the interaction of the α2M receptor with its ligand, such as HSPs, and methods for using compositions comprising α2M-receptor sequences for the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.

In some embodiments, the present disclosure relates to an avian-free egg white composition including 45-63% Ovalbumin, 9-15% Ovotransferrin, 0-15% Ovomucoid, 3-5% Ovoglobulin G2, 3-5% Ovoglobulin G3, 2.5-5% Ovomucin, 3-5% Lysozyme, 1-2% Ovoinhibitor, 0.8-1.5% Ovoglycoprotein, 0.6-1.0% Flavoprotein, 0.3-0.8% Ovomacroglobulin, 0.02-0.1% Avidin, and 0.02-0.1% Cystatin. In some embodiments, the composition includes an edible yeast and one or more of the preceding proteins. In some embodiments, the avian-free egg white further includes one or more of: flavor enhancers, calcium supplements, added vitamins, and a gelling agent. In some embodiments, the present disclosure pertains to a non-allergenic egg-white composition for human consumption. In some embodiments, the present disclosure pertains to methods of making the avian-free egg-white composition.

An assay for testing a subject for diabetes or a predisposition to diabetes including analysing a biological fluid from a subject for the presence of one or more proteins selected from the group consisting of Alpha 2 macroglobulin, Apolipoprotein All, Immunoglobulin alpha heavy chain constant region, Immunoglobulin mu chain C region, Chain A of Human IgA1, Inter-alpha-trypsin inhibitor heavy chain H4 precursor, and Apolipoprotein B100; wherein detection of the protein is indicative of diabetes or a predisposition to diabetes in the subject

A composition for treating a nucleic acid duplex, wherein the composition is capable of inhibiting denaturation of the duplex, characterised in that the composition comprises a ubiquitin-like protein and / or a macroglobulin. It has been found that ubiquitin-like proteins (e.g. ubiquitin, NEDD8, RAD23, etc.) and macroglobulins (eg. α2-macroglobulin) are able to stabilise nucleic acid duplexes. A nucleic acid duplex which has been contacted with the composition of the invention can be subjected to more stringent processing conditions, with denaturation of the duplex being inhibited, than would otherwise be possible. Corresponding methods and uses are also provided.

In some embodiments, the present disclosure relates to an avian-free egg white composition comprising 45-63% Ovalbumin, 9-15% Ovotransferrin, 0-15% Ovomucoid, 3-5% Ovoglobulin G2, 3-5% Ovoglobulin G3, 2.5-5% Ovomucin, 3-5% Lysozyme, 1-2% Ovoinhibitor, 0.8-1.5% Ovoglycoprotein, 0.6-1.0% Flavoprotein, 0.3-0.8% Ovomacroglobulin, 0.02-0.1% Avidin, and 0.02-0.1% Cystatin. In some embodiments, the composition comprises an edible yeast and one or more of the preceding proteins. In some embodiments, the avian-free egg white further comprises one or more of: flavor enhancers, calcium supplements, added vitamins, and a gelling agent. In some embodiments, the present disclosure pertains to a non-allergenic egg-white composition for human consumption. In some embodiments, the present disclosure pertains to methods of making the avian-free egg-white composition.

A drug for preventing vascular restenosis comprises a compound that inactivates α1-protease inhibitor and α2-macroglobulin as active constituents, which are associated with occurrence of vascular restenosis after coronary artery intervention. Preferably, the drug is coated on a surface of an implantable intravascular device and locally administered to the affected area by application of the implantable intravascular device to a narrowed area.

Activation of .alpha..sub.2-macroglobulin (.alpha..sub.2M) with a nucleophilic compound followed by incubation of the activated .alpha..sub.2M at elevated temperature with a biomolecule results in covalent incorporation of the intact biomolecule into the .alpha..sub.2M molecule, without the use of proteinases. The thus-formed structurally defined and stable complex may be used as an antigen for stimulating the immune response, for example, in the form of a vaccine. Enhanced antigen presentation of a particular biomolecule is provided, especially for those that are poorly immunogenic; reduction of the immunodominance of particular epitopes is also provided.

A method is provided for the localized intravascular administration of a fibrinolytic metalloproteinase to a human subject in amounts that are both safe and effective to lyse an occluding fibrin-containing blood clot, while also avoiding the neutralizing effects of α2-macroglobulin in the circulating blood. A method is also provided for the treatment of a blood clot in, around or attached to an indwelling vascular access device. A method for restoring patency and function of an indwelling vascular access device is also provided.

The invention discloses an AD biomarker and a detection method thereof. The AD biomarker comprises at least one of Protein-glutamine gamma-glutamyltransferase E, Protein S100-A12, Alph-2-macroglobulin-like protein 1, Polymeric immunoglobulin receptor, Myeloperoxidase, Peroxiredoxin-1, Protein S100-A11, Alpha-2-macroglobulin, Cystatin-C, Histone H2A, Histone H2B, Tubulin alpha-1B and Annexin A3.

The invention relates to the technical field of in vitro immunodiagnosis detection of alpha 2-macroglobulin (alpha 2-MG), in particular to an alpha 2-MG detection kit. A reagent R1 contains a buffer solution, NaCl, PEG-6000, undecylcarboxymethyl sodium type imidazoline acetate, and a preservative, a reagent R2 contains a buffer solution, goat anti-human alpha 2-MG antibody-coated latex particles,casein, gelatin, glycerin, trehalose, undecylcarboxymethyl sodium type imidazoline acetate, preservative. The kit disclosed by the invention significantly improves the stability and linear range of the reagent, and significantly enhances the sensitivity and accuracy of the reagent.

The invention relates to the field of biomedical engineering, and discloses a dressing for promoting wound healing and a preparation method thereof, comprising (1)α 2 Purification of macroglobulin; (2) dissolving blue copper peptide, copper sulfate, leupeptin, carboxymethyl chitosan and polyethylene oxide in water, stirring evenly, adding α 2 The macroglobulin solution is used to obtain a spinning solution; (3) the spinning solution is used for electrospinning to obtain a dressing for promoting wound healing. The dressing for promoting wound healing prepared by the invention is a medical material capable of inducing wound healing for a long time, can accelerate wound healing, and is very effective in treating wounds and skin damage.

The invention belongs to the field of biotechnologies and relates to an assay kit for diagnosis of hypertensive disorders of pregnancy. The assay kit comprises specific antibodies respectively aiming at Kertin, Alpha-actinin-4, Afamin, Alpha-2-macroglobulin, ALB, SERPINA1, Vimentin, Tubulin beta-2C chain and / or angiotensinogen protein. The assay kit can detect multiple proteins which are expressed differentially and are in urine samples of patients suffering from hypertensive disorders of pregnancy. Information of the above multiple proteins expressed differentially can be as a basis for the research of pathogenesis of preeclampsia nephropathy proteinuria, and provides a clue for the search of biomarkers utilized for an early diagnosis and a forecast of preeclampsia nephropathy. The assay kit provided by the invention is a non-invasive detecting tool of biomarkers of hypertensive disorders of pregnancy, and can be utilized for diagnosing preeclampsia nephropathy and hypertensive disorders of pregnancy.

A2M polypeptide compositions containing a non-natural bait region are disclosed. Methods of producing wild-type and variant A2M polypeptides and polynucleotides containing a non-natural bait region are also disclosed. The bait regions of the variant A2M polypeptides demonstrate enhanced protease inhibitory characteristics compared to wild-type A2M. Variant A2M polypeptides that demonstrate longer half-lives upon administration to an organism compared to wild-type A2M are disclosed. The A2M compositions are useful in treating a number of diseases and conditions including inflammation, chronic wounds, and diseases with a pathology associated with proteases.

The present invention discloses a method for separating and purifying α2-macroglobulin from Cohn Fraction IV precipitation, in which Cohn Fraction IV precipitation is treated by ammonium sulfate precipitation, zinc ion affinity chromatography, gel filtration, and ultrafiltration and concentration sequentially and thereby α2-macroglobulin is obtained finally. With the method provided in the present invention, purified α2-macroglobulin plasma protein that has a clinical application value is obtained, the Cohn Fraction IV precipitation is changed from a discarded material into a valuable material, and plasma is utilized comprehensively. In addition, the method is easy and simple to use, easy to scale up, and suitable for separation and purification of α2-macroglobulin at a large scale.